Literature DB >> 16867653

Handling of biological samples in the determination of the anti-neoplastic drug mitomycin C.

J den Hartigh1, G Voortman, W J van Oort, H Weenen, H M Pinedo.   

Abstract

A study to ascertain suitable conditions for handling biological samples from patients, treated with the antibiotic mitomycin C (MMC), with the objective of improving the accuracy and reliability of the determination is described. Situations frequently occurring in medical practice are simulated to optimize procedures for reliable and reproducible sampling, sample treatment and determination of MMC. Continuation of drug partitioning in whole blood after sampling can be prevented by immediate cooling in ice before the separation of plasma from cells. The adjustment of the pH of urine samples is shown to be particularly important since a low urinary pH causes decomposition of MMC; moreover, it may decrease extraction recovery. Furthermore, long-term exposure of samples to daylight induces drug decomposition. Frozen storage of plasma and urine samples for periods greater than 3 weeks is to be avoided as this results in a considerable drop in MMC concentration. Repeated cycles of freezing and thawing are shown to have no effect upon the analytical results (6 cycles tested). The analysis of extracts of biological samples may take place up to at least 24 h after their preparation without measurable loss of analyte.

Entities:  

Year:  1985        PMID: 16867653     DOI: 10.1016/0731-7085(85)80055-8

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Absence of interaction between furosemide and mitomycin C.

Authors:  J Verweij; S Kerpel-Fronius; M Stuurman; J de Vries; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Relationship between clinical parameters and pharmacokinetics of mitomycin C.

Authors:  J Verweij; J den Hartigh; M Stuurman; J de Vries; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study.

Authors:  Olaf Sørensen; Anders Andersen; Harald Olsen; Kristian Alexandr; Per Olaf Ekstrøm; Karl-Erik Giercksky; Kjersti Flatmark
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

4.  Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.

Authors:  S Kerpel-Fronius; J Verwey; M Stuurman; B Kanyár; P Lelieveld; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Pharmacokinetics of mitomycin C in patients after bolus injection and chemobolisation of the hepatic artery with Spherex starch particles.

Authors:  M J Czejka; W Jäger; J Schüller
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

6.  PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3.

Authors:  Guus Martinus Bol; Raheela Khan; Marise Rosa Heerma van Voss; Saritha Tantravedi; Dorian Korz; Yoshinori Kato; Venu Raman
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-02       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.